Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharma) will convene its 2026 annual general meeting (AGM) on 27 May 2026 at 10:00 a.m. in Fuzhou, Fujian Province, the People’s Republic of China.

Key items up for shareholder approval include:

1. 2025 Operating and Oversight Reports • Submission of the Board of Directors’ and Board of Supervisors’ work reports for 2025. • Presentation of audited consolidated financial statements, the independent auditor’s report, and the 2025 annual and ESG reports. • Approval of the 2025 final accounts and profit-distribution plan.

2. External Auditor and Director Remuneration • Re-appointment of the external auditor for 2026 with the Board authorised to set fees. • Determination of directors’ remuneration for 2026.

3. Credit Facilities and Guarantees • Authorisation for the Company to apply for comprehensive bank credit lines and to provide corresponding guarantees during 2026.

4. Corporate Governance Changes • Proposed abolishment of the Board of Supervisors. • Amendments to the Rules of Procedure for Shareholders’ Meetings and for Board Meetings.

5. Board Refresh • Election of nine directors for the second Board term: four executive directors (Kang Xinshan, Feng Yan, Chen Guangming, Li Junqing), two non-executive directors (Xu Dong, Wang Xinkun) and three independent non-executive directors (Wang Shan Shan, Pu Meiting, Lin Bin).

6. Capital Management and Incentives • Capital increase in the Hong Kong subsidiary. • Formulation of a share incentive scheme implementation plan. • Renewal of general mandates to issue and to repurchase shares.

Record Date and Voting Arrangements The register of members will be closed from 21 May 2026 to 27 May 2026 (both days inclusive). Shareholders recorded on 27 May 2026 are entitled to attend and vote, either in person or by proxy. Proxy forms must be lodged with Tricor Investor Services Limited no later than 24 hours before the AGM.

The full text of each resolution is detailed in the circular issued on 30 April 2026 and the official notice filed with Hong Kong Exchanges and Clearing Limited.